Track Integrated Media Technology Limited (IMTE) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors187.61%. BEAT. Home. Symbol. UPST. Earnings. Checkout Upstart Holdings Inc (UPST) earnings results, EPS expectations and actual EPS values for both quarterly and annual periods. Discover whether UPST beat the street expectations or not?Vulvar pain is a common side effect of menstruation, but it could also be a sign of a medical condition. Here are the main causes of vulvar pain plus prevention tips and treatment ...Tempest Therapeutics, Inc. (TPST) Interactive Stock Chart - Yahoo Finance. NasdaqCM - Nasdaq Real Time Price • USD. Tempest Therapeutics, Inc. (TPST) 3.4750 -0.1450 (-4.01%) As of... Track Milady(LADYS) Price, real-time chart movements, latest community messages, chart, news and related information. Share your ideas and get valuable insights from the community of like minded traders and investors InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Tempest Therapeutics (NASDAQ:TPST) is the stock to watch for today, as its shares are up by a staggering 1,500%.This morning, the ...May 9, 2024 · marketbeat.com - April 13 at 1:10 PM. Tempest Therapeutics (NASDAQ:TPST) Trading Down 6.8%. marketbeat.com - April 13 at 12:40 AM. Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments. markets.businessinsider.com - April 9 at 5:53 PM. TPST on StockTwits; TPST on Twitter; Tempest Therapeutics, Inc. Description. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and …BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights plan ...I don't know what it is about your thirties — or maybe for you, it's your forties, fifties, or sixties — that you just start to feel really freakin�...TPST Competitors. $ Market cap P/E ratio $ Price 1d change 52-week range. View Tempest Therapeutics, Inc. TPST stock quote prices, financial information, real-time forecasts, and company news from ...Track Intel Corp (INTC) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe latest messages and market ideas from Top Stock Alerts (@topstockalerts) on Stocktwits. Owner of Top Stock Alerts. A Trading Community For Beginners And Experienced Traders. Join The Team Today To Receive Premium Alerts. Dont Miss Our Next PREMIUM ALERT! 📱🌍 Posts are not recommendations. Not a financial advisorTrack SeaStar Medical Holding Corp (ICU) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Spotify Technology S.A. (SPOT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTempest Therapeutics TPST stock skyrocketed 2879% after it announced positive new data from its global phase Ib/II first-line liver cancer study, evaluating TPST-1120, in combination with the ...The company’s two novel clinical programs, TPST-1120 and TPST-1495, target PPARα and EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in ...TPST-1120 showed tolerable safety profile as monotherapy and in combination with nivolumab. Most common treatment related AEs were nausea, fatigue and diarrhea. No DLTs during dose escalation. RP2D 600 mg PO BID for monotherapy and combination. Discover historical prices for TPST stock on Yahoo Finance. View daily, weekly or monthly format back to when Tempest Therapeutics, Inc. stock was issued. Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.Track Palantir Technologies Inc (PLTR) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Tempest Therapeutics Inc (TPST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Upstart Holdings Inc (UPST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Avadel Pharm Sp ADR (AVDL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST …A travel journalist shows you why he's earning more Wyndham Rewards points this year. Wyndham Rewards has long been a program I've watched closely but never earned or redeemed poin...Per-Share Earnings, Actuals and Estimates. View the latest Tempest Therapeutics Inc. (TPST) stock price, news, historical charts, analyst ratings and financial information from WSJ.Track Cellectis (CLLS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe latest messages and market ideas from Mark Trotto (@pst) on Stocktwits. The largest community for investors and traders. The latest messages and market ideas from Mark Trotto (@pst) on Stocktwits. ... pst. Mark Trotto. Follow. Strategy: Joined 7/2012. 3 Following 1 Followers. 0 Posts. 0 Liked. 0 Watchlist.Matador is a travel and lifestyle brand redefining travel media with cutting edge adventure stories, photojournalism, and social commentary. IT’S SUNDAY. Wake up. Your husband is a...TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Companyâ s …The company’s two novel clinical programs, TPST-1120 and TPST-1495, target PPARα and EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in ...StockTwits Stats. Metric Count No Of Stocks (discussed) 1337 No Of Comments 16858 No Of Comments (followers >100) 4443 Most Active Stocks On StockTwits. Click on Table headers to sort. Ticker No Of Comments; AMC: 378: GME: 363: NVAX: 328: TSLA: 271: JAGX: 267: OCGN: 261: MULN: 235: DJT: 224: GNS ...TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Companyâ s …TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Companyâ s …Track PureCycle Technologies Inc (PCT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC studyNew capital strengthens balance sheet and extends cash runway into ...Oct 11, 2023 · TPST stock is now up by more than 220% this year. Tempest Therapeutics (NASDAQ: TPST) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer ... Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation …Social anxiety can cause feelings like loneliness and inadequacy that can lead to developing depression. Social anxiety can sometimes lead to depression, but the right support can ...TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Companyâ s …Ideas. TPST (Tempest Therapeutics | NASDAQ:TPST) Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The stock closed at $9.77 a.Vulvar pain is a common side effect of menstruation, but it could also be a sign of a medical condition. Here are the main causes of vulvar pain plus prevention tips and treatment ...Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation …Track PureCycle Technologies Inc (PCT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsLearning the ins and outs of an eCommerce business requires you to learn many of the same lessons that you’ll need to create a new business in general. Still, there are also some u...TPST stock is now up by more than 220% this year. Tempest Therapeutics (NASDAQ: TPST) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer ... Track Senti Biosciences Inc. (SNTI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Track Poseida Therapeutics Inc (PSTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting. More news. 44th Annual TD Cowen Healthcare Conference. TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call. Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.Analyst Recommendations on Tempest Therapeutics, Inc. Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13. Mar. 14. MT. HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating. 23-10-11.Oct 12, 2023 · Tempest Therapeutics (NASDAQ: TPST) stock is up 3,800% on the full day. TPST stock has reacted to the company’s announcement that it’s drug for a certain type of liver cancer seems to actually work. OK, we might think that 3,800% is rather too much for just that announcement - this isn’t FDA approval and all that as yet. Tempest Therapeutics (NASDAQ: TPST) stock is up 3,800% on the full day. TPST stock has reacted to the company’s announcement that it’s drug for a certain type of liver cancer seems to actually work. OK, we might think that 3,800% is rather too much for just that announcement - this isn’t FDA approval and all that as yet.Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to ...The latest messages and market ideas from EML to PST converter (@PatrickRoggers) on Stocktwits. Shoviv EML to PST converter easily convert EML files into Outlook PST format.TPST stock is up 325% as of Wednesday morning but was down 80.5% when markets closed yesterday. Investors on the lookout for more of the most recent stock market stories will want to stick around!The company’s two novel clinical programs, TPST-1120 and TPST-1495, target PPARα and EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in ...TPST stock is up 325% as of Wednesday morning but was down 80.5% when markets closed yesterday. Investors on the lookout for more of the most recent stock market stories will want to stick around!Tempest Therapeutics Inc ( TPST) has gained Tuesday morning, with the stock climbing 2.58% in pre-market trading to 3.18. TPST's short-term technical score of 40 indicates that the stock has traded less bullishly over the last month than 60% of stocks on the market. In the Biotechnology industry, which ranks 129 out of 146 industries, the stock ...Track AT&T Inc (T) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThird Quarter 2023. Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022. Net loss and net loss per share for the quarter ...Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting. BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at ...Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST …Stock Twits (@stocktwits) is the largest social network for investors and traders. Follow the latest news, insights, and ideas on stocks, crypto, futures, and more. Join the conversation and share your own opinions with millions of users. Stock Twits - where money talks.Track Cellectis (CLLS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Invesco Capital Management LLC - PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares (PST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe SMN1 gene provides instructions for making the survival motor neuron (SMN) protein. Learn about this gene and related health conditions. The SMN1 gene provides instructions for...Stock analysis for Tempest Therapeutics Inc (TPST:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Track TG Therapeutics Inc (TGTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Track Milady(LADYS) Price, real-time chart movements, latest community messages, chart, news and related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST …Discover historical prices for TPST stock on Yahoo Finance. View daily, weekly or monthly format back to when Tempest Therapeutics, Inc. stock was issued. Fundamentals. Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA. Sector: Find Invesco Capital Management LLC - PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares (PST) news, corporate events, press releases, latest company updates and headlinesTempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 …TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC studyNew capital strengthens balance sheet and extends cash runway into ...Tempest Therapeutics, Inc. TPSTNasdaq Stock Market. 3.25USD. −0.22 −6.34% At close at May 10, 16:48 UTC-7. See on Supercharts. Overview. Financials News Ideas Technicals Forecast. TPST chart. 1 day −6.34% …View Invesco Capital Management LLC - PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares (PST) company profile, FAQs, interesting facts, information about industry, sector and employeesTempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST …Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation … Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual ... Brady expressed optimism about TPST-1120's potential and laid out multiple strategies for approval. In addition to the promising drug results, Brady introduced a limited-duration stockholder ...Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual ...Track Ouster Inc - Ordinary Shares - Class A (OUST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThird Quarter 2023. Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022. Net loss and net loss per share for the quarter ...You’re sitting in a meeting and a co-worker takes credit for your idea. Or maybe you stay late to finish a p You’re sitting in a meeting and a co-worker takes credit for your idea....Ideas. TPST (Tempest Therapeutics | NASDAQ:TPST) Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The stock closed at $9.77 a.Track 2seventy bio Inc (TSVT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack TG Therapeutics Inc (TGTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 …
The company said unconfirmed responses of 30% for the TPST-1120 group (12/40), versus 17.2% for the control group (5/29), showed a 74.4% relative improvement in objective response rate (ORR).. Boosie concert san antonio
Penjabat Wali Kota Bandung, Bambang Tirtoyuliono mengatakan empat TPST yang beroperasi menggunakan teknologi tersebut antara lain, Babakan Siliwangi (Baksil), Jalan Indramayu, Ence Azis dan Batununggal. “Dengan adanya teknologi RDF ini, timbunan sampah Kota Bandung ke TPA Sarimukti berkurang,” kata Bambang di …Ideas. TPST (Tempest Therapeutics | NASDAQ:TPST) Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The stock …Track SeaStar Medical Holding Corp (ICU) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTempest Therapeutics, Inc. (TPST) Follow. 3.2500 -0.2200 (-6.34%) At close: May 10 at 4:00 PM EDT. 3.3100 +0.06 (+1.85%) After hours: May 10 at 7:48 PM EDT. Conversations. Community Insights....Only people giving up there shares are the ones for sale which clearly isn’t many…..Per wallet investor- iQSTEL Inc quote is equal to 0.359 USD at 2024-05-12. Based on our forecasts, a long-term increase is expected, the "IQST" stock price prognosis for 2029-05-02 is 66.107 USD. Reply. TipRanks | Stock Market Research, News and Analyst Forecasts ... designer491. Shares of Tempest Therapeutics ( NASDAQ: TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first ...6 days ago · 4 brokerages have issued 1 year price targets for Tempest Therapeutics' shares. Their TPST share price targets range from $13.00 to $47.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 669.2% from the stock's current price. Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat ...TPST stock was up 107.3% as of Monday morning but is only up 3.8% since the start of the year. Investors looking for more stock market news today will want to keep reading.Ideas. TPST (Tempest Therapeutics | NASDAQ:TPST) Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The stock …Ideas. TPST (Tempest Therapeutics | NASDAQ:TPST) Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The stock closed at $9.77 a.Tempest Therapeutics Inc ( TPST) has gained Tuesday morning, with the stock climbing 2.58% in pre-market trading to 3.18. TPST's short-term technical score of 40 indicates that the stock has traded less bullishly over the last month than 60% of stocks on the market. In the Biotechnology industry, which ranks 129 out of 146 industries, the stock ...Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.Brady expressed optimism about TPST-1120's potential and laid out multiple strategies for approval. In addition to the promising drug results, Brady introduced a limited-duration stockholder ...Oct 5, 2023 · As of October 5, 2023, the average one-year price target for Tempest Therapeutics is 15.98. The forecasts range from a low of 4.04 to a high of $36.75. The average price target represents an ... TipRanks Track Pershing Square Tontine Holdings Ltd - Ordinary Shares - Class A (PSTH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Stock analysis for Tempest Therapeutics Inc (TPST:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.See the latest Tempest Therapeutics Inc stock price (TPST:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Pantginis also raised his price target for Tempest Therapeutics from $35 to $47, based on an increased projected chance of success for TPST-1120 in HCC, from 15% to 25%..